MedPath

Aspirin

Generic Name
Aspirin
Brand Names
Aggrenox, Alka-seltzer, Alka-seltzer Fruit Chews, Anacin, Arthriten Inflammatory Pain, Ascomp, Aspi-cor, Aspir-low, Bayer Aspirin, Bayer Womens, Bc Arthritis, Bc Original Formula, Bufferin, Duoplavin, Durlaza, Ecotrin, Ecpirin, Endodan Reformulated May 2009, Equagesic, Exaprin, Excedrin, Excedrin PM Triple Action, Fasprin, Fiorinal, Goody's Body Pain, Goody's Extra Strength, Goody's PM, Miniprin, Norgesic, Norgesic Forte, Orphengesic, Pamprin Max Formula, Robaxisal, ST. Joseph Aspirin, Stanback Headache Powder Reformulated Jan 2011, Trianal, Trianal C, Vanquish, Vazalore, Yosprala
Drug Type
Small Molecule
Chemical Formula
C9H8O4
CAS Number
50-78-2
Unique Ingredient Identifier
R16CO5Y76E
Background

Also known as Aspirin, acetylsalicylic acid (ASA) is a commonly used drug for the treatment of pain and fever due to various causes. Acetylsalicylic acid has both anti-inflammatory and antipyretic effects. This drug also inhibits platelet aggregation and is used in the prevention of blood clots stroke, and myocardial infarction (MI) .

Interestingly, the results of various studies have demonstrated that long-term use of acetylsalicylic acid may decrease the risk of various cancers, including colorectal, esophageal, breast, lung, prostate, liver and skin cancer . Aspirin is classified as a non-selective cyclooxygenase (COX) inhibitor and is available in many doses and forms, including chewable tablets, suppositories, extended release formulations, and others .

Acetylsalicylic acid is a very common cause of accidental poisoning in young children. It should be kept out of reach from young children, toddlers, and infants .

Indication

Pain, fever, and inflammation

Acetylsalicylic acid (ASA), in the regular tablet form (immediate-release), is indicated to relieve pain, fever, and inflammation associated with many conditions, including the flu, the common cold, neck and back pain, dysmenorrhea, headache, tooth pain, sprains, fractures, myositis, neuralgia, synovitis, arthritis, bursitis, burns, and various injuries. It is also used for symptomatic pain relief after surgical and dental procedures .

The extra strength formulation of acetylsalicylic acid is also indicated for the management migraine pain with photophobia (sensitivity to light) and phonophobia (sensitivity to sound).

Other indications

ASA is also indicated for various other purposes, due to its ability to inhibit platelet aggregation. These include:

Reducing the risk of cardiovascular death in suspected cases of myocardial infarction (MI) .

Reducing the risk of a first non-fatal myocardial infarction in patients, and for reducing the risk of morbidity and mortality in cases of unstable angina and in those who have had a prior myocardial infarction .

For reducing the risk of transient ischemic attacks (TIA) and to prevent atherothrombotic cerebral infarction (in conjunction with other treatments) .

For the prevention of thromboembolism after hip replacement surgery .

For decreasing platelet to platelet adhesion following carotid endarterectomy, aiding in the prevention of transient ischemic attacks (TIA) .

Used for patients undergoing hemodialysis with a silicone rubber arteriovenous cannula inserted to prevent thrombosis at the insertion site .

Important note regarding use of the extended-release formulation

In the setting of acute myocardial infarction, or before percutaneous interventions, the extended-release form of acetylsalicylic acid should not be used. Use immediate-release formulations in scenarios requiring rapid onset of action . The extended-release form is taken to decrease the incidence of mortality and myocardial infarction (MI) for individuals diagnosed with chronic coronary artery disease (CAD), including patients with previous myocardial infarction (MI) or unstable angina or with chronic stable angina. Additionally, the extended-release form is used to decrease the risk of death and recurrent episodes of stroke in patients with a history of stroke or TIA .

Associated Conditions
Acute Coronary Syndrome (ACS), Anxiety, Atherothrombotic cerebral infarction, Cardiovascular Disease (CVD), Cardiovascular Events, Cardiovascular Mortality, Colorectal Adenomas, Colorectal Cancer, Common Cold, Coronary artery reocclusion, Death, Dyspeptic signs and symptoms, Fever, Flu caused by Influenza, Headache, Heterozygous Familial Hypercholesterolemia (HeFH), Inflammation, Juvenile Idiopathic Arthritis (JIA), Major Adverse Cardiovascular and Cerebrovascular Events (MACCE), Menstrual Pain, Migraine, Morbidity, Mucocutaneous Lymph Node Syndrome, Muscle Contraction, Myalgia, Myocardial Infarction, Myocardial Infarction (MI), first occurrence, Neuropathic Pain, Pain, Pain caused by Common Cold, Pain caused by Rheumatism, Pericarditis, Polycythemia Vera (PV), Pre-Eclampsia, Rheumatism, Rheumatoid Arthritis, Rhino Sinusitis, Severe Pain, Spondyloarthropathies, Stroke, Systemic Lupus Erythematosus, Tension Headache, Thromboembolism, Thrombosis, Toothache, Transient Ischemic Attack, Vascular Death, Venous Thromboembolism, Acute Inflammation, Articular inflammation, Atherothrombotic events, Death caused by Myocardial Infarction, Fever or influenza-like illness, Moderate Pain, Recurrent Ischemic Stroke
Associated Therapies
Anti-platelet Therapy, Hemodialysis Treatment, Secondary Prevention

Warfarin Prevents Portal Vein Thrombosis in Patients After Laparoscopic Splenectomy and Azygoportal Disconnection

Phase 4
Completed
Conditions
Cirrhosis
Hypertension
Status;Splenectomy
Venous Thrombosis
Interventions
Drug: Warfarin
Drug: Dipyridamole
Drug: Aspirin
Drug: Low Molecular Weight Heparin
First Posted Date
2014-09-25
Last Posted Date
2019-03-29
Lead Sponsor
Yangzhou University
Target Recruit Count
124
Registration Number
NCT02247414
Locations
🇨🇳

Clinical Medical College of Yangzhou University, Yangzhou, Jiangsu, China

Study of Platelet Function After Administration of Aspirin Versus Lysine Acetylsalicylate

Phase 1
Completed
Conditions
Adverse Effect of Antithrombotic Drugs
Interventions
Drug: acetylsalicylic acid
Drug: lysine acetylsalicylate
Drug: prasugrel
First Posted Date
2014-09-17
Last Posted Date
2014-09-17
Lead Sponsor
David Vivas
Target Recruit Count
30
Registration Number
NCT02243137
Locations
🇪🇸

Hospital Clínico San Carlos, Madrid, Spain

Warfarin Prevents Portal Vein Thrombosis in Liver Cirrhotic Patients With Hypersplenism After Laparoscopic Splenectomy

Phase 4
Conditions
Cirrhosis
Hypertension
Status; Splenectomy
Venous Thrombosis
Interventions
Drug: Warfarin
Drug: Dipyridamole
Drug: Aspirin
Drug: Low Molecular Weight Heparin
First Posted Date
2014-09-12
Last Posted Date
2019-01-02
Lead Sponsor
Yangzhou University
Target Recruit Count
60
Registration Number
NCT02238444
Locations
🇨🇳

Clinical Medical College of Yangzhou University, Yangzhou, Jiangsu, China

Pharmacogenomics of Antiplatelet Response

Phase 4
Completed
Conditions
Atherosclerosis
Interventions
First Posted Date
2014-09-09
Last Posted Date
2017-01-09
Lead Sponsor
Johns Hopkins University
Target Recruit Count
34
Registration Number
NCT02234427
Locations
🇺🇸

Johns Hopkins School of Medicine, Baltimore, Maryland, United States

Mechanism of Dipyridamole Action in Platelets: in Vivo Study With Healthy Volunteers

Phase 1
Completed
Conditions
Healthy
Interventions
First Posted Date
2014-08-27
Last Posted Date
2014-08-27
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
15
Registration Number
NCT02226926

COBRA SHIELD OCT Study

Not Applicable
Terminated
Conditions
Stable Angina
Interventions
Device: COBRA PzF
Device: Resolute Integrity DES
Drug: Aspirin
Drug: DAPT
First Posted Date
2014-08-25
Last Posted Date
2020-10-06
Lead Sponsor
CeloNova BioSciences, Inc.
Target Recruit Count
8
Registration Number
NCT02224235
Locations
🇫🇮

Heart Center, Turku University Hospital, Turku, Finland

🇫🇮

Satakunta Central Hospital, Pori, Finland

Edoxaban for TIA and Acute Minor Stroke

Phase 2
Conditions
Stroke
Cerebral Infarction
Ischemia
Interventions
First Posted Date
2014-08-20
Last Posted Date
2014-08-20
Lead Sponsor
Xijing Hospital
Target Recruit Count
3700
Registration Number
NCT02221102
Locations
🇨🇳

Xijing Hospital, Xi'an, Shaanxi, China

Arachidonic Acid-induced Platelet Aggregation Rate in Patients With Stable CAD Treated With Ticagrelor Monotherapy

Phase 4
Completed
Conditions
Coronary Heart Disease
Interventions
First Posted Date
2014-08-18
Last Posted Date
2016-06-21
Lead Sponsor
Yong Huo
Target Recruit Count
70
Registration Number
NCT02219412
Locations
🇨🇳

Peking University First Hospital, Beijing, China

Efficacy of Ticagrelor vs Clopidogrel in High-risk NSTE-ACS Patients Undergoing Early PCI

Phase 4
Conditions
Acute Coronary Syndrome
Interventions
First Posted Date
2014-07-28
Last Posted Date
2014-08-04
Lead Sponsor
RenJi Hospital
Target Recruit Count
444
Registration Number
NCT02201667
Locations
🇨🇳

Ren Ji Hospital Afflited to School of Medicine, Shanghai Jiao Tong University, Shanghai, Shanghai, China

Different Antiplatelet Therapy Strategy After Coronary Artery Bypass Graft Surgery

Phase 4
Completed
Conditions
Coronary Artery Bypass
Antiplatelet Agents
Interventions
First Posted Date
2014-07-28
Last Posted Date
2019-08-13
Lead Sponsor
Ruijin Hospital
Target Recruit Count
500
Registration Number
NCT02201771
Locations
🇨🇳

Xinhua Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, Shanghai, China

🇨🇳

Nan Jing First Hospital, Nanjing, Jiangsu, China

🇨🇳

Henan Provincial People's Hospital, Zhengzhou, Henan, China

and more 3 locations
© Copyright 2025. All Rights Reserved by MedPath